丁苯酞联合依达拉奉治疗急性脑梗死的临床效果分析

Analysis of Clinical Effect of Butylphthalide Combined with Edaravone in Treatment of Acute Cerebral Infarction

目的:分析丁苯酞联合依达拉奉治疗急性脑梗死的临床效果。方法:选取2018年6月-2020年12月湖北科技学院附属医院麻城市人民医院收治的急性脑梗死患者120例作为研究对象,随机分为两组,每组60例。两组均给予常规治疗,对照组在常规治疗基础上给予依达拉奉,治疗组在对照组基础上给予丁苯酞。比较两组临床疗效、神经功能、凝血功能、炎性因子水平。结果:治疗前,两组美国国立卫生研究院卒中量表(NIHSS)评分比较,差异无统计学意义(P>0.05);治疗后,两组NIHSS评分低于治疗前,且治疗组低于对照组,差异有统计学意义(P<0.05)。治疗组治疗有效率高于对照组,差异有统计学意义(P<0.001)。治疗前,两组D-二聚体水平、纤维蛋白原水平、凝血酶时间、活化部分凝血活酶时间比较,差异无统计学意义(P>0.05);治疗后,两组D-二聚体、纤维蛋白原水平低于治疗前,且治疗组低于对照组,两组凝血酶时间、活化部分凝血活酶时间长于治疗前,且治疗组长于对照组,差异有统计学意义(P<0.05)。治疗前,两组超敏C反应蛋白、白细胞介素-6水平比较,差异无统计学意义(P>0.05);治疗后,两组超敏C反应蛋白、白细胞介素-6水平低于治疗前,且治疗组低于对照组,差异有统计学意义(P<0.05)。结论:丁苯酞联合依达拉奉治疗急性脑梗死的临床效果显著,可改善患者神经功能、凝血功能,减轻炎性反应。

Objective:To analyze the clinical effect of butylphthalide combined with edaravone in the treatment of acute cerebral infarction.Methods:A total of 120 patients with acute cerebral infarction admitted to the People's Hospital of Macheng City,Affiliated Hospital of Hubei University of Science and Technology between June 2018 and December 2020 were selected as the study subjects.They were randomly allocated into two groups,with 60 patients in each group.Both groups received conventional treatment.The control group was treated with edaravone on the basis of conventional treatment.The treatment group was treated with butylphthalide on the basis of control group.The clinical efficacy,neurological function,coagulation function and levels of inflammatory factors were compared between two groups.Results:Before treatment,there was no significant difference in the scores of National Institutes of Health Stroke Scale(NIHSS)between the two groups(P>0.05).After treatment,the NIHSS scores in the two groups were lower than those before treatment,and the scores in the treatment group were lower than those in the control group,with a statistically significant difference(P<0.05).The effective rate in the treatment group was higher than that in the control group,and the difference was statistically significant(P<0.001).Before treatment,there was no significant difference in Ddimer level,fibrinogen level,thrombin time,and activated partial thromboplastin time between the two groups(P>0.05).After treatment,the levels of D-dimer and fibrinogen in the two groups were lower than those before treatment,and the levels in the treatment group were lower than those in the control group,while the thrombin time and activated partial thromboplastin time in the two groups were longer than those before treatment,and these indicators in the treatment group were longer than those in the control group,and the difference was statistically significant(P<0.05).Before treatment,there was no significant difference in the levels of hypersensitive C-reactive protein and interleukin-6 between the two groups(P>0.05).After treatment,the levels of hypersensitive C-reactive protein and interleukin-6 in the two groups were lower than those before treatment,and the levels in the treatment group were lower than those in the control group,with a statistically significant difference(P<0.05).Conclusion:Butylphthalide combined with edaravone has significant clinical effect in the treatment of acute cerebral infarction,and can improve the neurological function and coagulation function of patients,and reduce inflammatory reactions.